Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy-Reference-Cited by-同舟云学术

Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy

Published:2023-10-28 Issue:12 Volume:129 Page:1988-2002
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Feng Xiaoshuang,Zhang Yiwen^ORCID,Vaselkiv J. Bailey,Li Ruifeng,Nguyen Paul L.,Penney Kathryn L.,Giovannucci Edward L.^ORCID,Mucci Lorelei A.,Stopsack Konrad H.^ORCID

Funder

Prostate Cancer Foundation

Zhu Family Center for Global Cancer Prevention

American Cancer Society

U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-023-02472-y.pdf

Reference52 articles.

1. Kilpeläinen TP, Tammela TL, Roobol M, Hugosson J, Ciatto S, Nelen V, et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer. 2011;47:2698–705.

2. Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E. Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol. 2010;28:1714–20.

3. Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. J Am Med Assoc. 2018;319:1901–13.

4. Kilpeläinen TP, Tammela TL, Määttänen L, Kujala P, Stenman UH, Ala-Opas M, et al. False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer. 2010;102:469–74.

5. Lewicki P, Shoag J, Golombos DM, Oromendia C, Ballman KV, Halpern JA, et al. Prognostic significance of a negative prostate biopsy: an analysis of subjects enrolled in a prostate cancer screening trial. J Urol. 2017;197:1014–9.